TerminatedPhase 2NCT06042257
Guanfacine for Hyperactivity in Children With Down Syndrome (HYPEbeGONE_DS)
Studying Down syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Rachel G. Greenberg, MD, MB, MHS
- Principal Investigator
- Rachel GreenbergDCRI
- Intervention
- Guanfacine Hydrochloride Immediate Release(drug)
- Enrollment
- 3 enrolled
- Eligibility
- 6-12 years · All sexes
- Timeline
- 2024 – 2025
Study locations (15)
- Phoenix Childrens Hospital, Phoenix, Arizona, United States
- Yale University School of Medicine, New Haven, Connecticut, United States
- Emory University, Atlanta, Georgia, United States
- Ann and Robert H. Lurie Hospital of Chicago, Chicago, Illinois, United States
- University of Iowa, Iowa City, Iowa, United States
- Kennedy Krieger Institute, Baltimore, Maryland, United States
- Boston Children's Hospital, Boston, Massachusetts, United States
- Massachusetts General Hospital, Lexington, Massachusetts, United States
- Atrium Health-Wake Forest School of Medicine, Charlotte, North Carolina, United States
- Duke University Hospital, Durham, North Carolina, United States
- Akron Children's Hospital, Akron, Ohio, United States
- Cincinnati Children's Hospital, Cincinnati, Ohio, United States
- Virginia Center for Children, Richmond, Virginia, United States
- University of Washington, Seattle, Washington, United States
- University of Wisconsin Madison, Madison, Wisconsin, United States
Collaborators
The Emmes Company, LLC · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06042257 on ClinicalTrials.govOther trials for Down syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07416201Natural History of Dysregulation and Aging of the Immune System in People With Trisomy 21 With and Without ThymectomyNational Institute of Allergy and Infectious Diseases (NIAID)
- RECRUITINGNANCT07484464Effects of the Otago Exercise Program on Balance, Endurance, and Motor Coordination in Children With Down SyndromeRiphah International University
- RECRUITINGNANCT07296861HomeGrown: A Family-based Lifestyle Intervention to Support Healthy Development of Young Children With Down SyndromeUNC Lineberger Comprehensive Cancer Center
- RECRUITINGNCT07195253Oro-myofunctional Characteristics and Obstructive Sleep Apnea in Infants With Down SyndromeHospices Civils de Lyon
- RECRUITINGNANCT07425769Adapting RDAD for DSUniversity of Kansas Medical Center
- ENROLLING BY INVITATIONNCT07413224Qualitative Effects of AEF0217 in Down Syndrome PeopleAelis Farma
- RECRUITINGPHASE4NCT07280468Endotype DIrected Treatment for OSA in Down SyndromeUniversity of Arizona
- RECRUITINGPHASE2NCT07242638Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down SyndromeIcahn School of Medicine at Mount Sinai